These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

836 related items for PubMed ID: 12051110

  • 1. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
    Dew JE, Wren BG, Eden JA.
    Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folkerd EJ, Willett WC, Wolmark N, Hankinson SE.
    J Natl Cancer Inst; 2006 Jan 18; 98(2):110-5. PubMed ID: 16418513
    [Abstract] [Full Text] [Related]

  • 4. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M, Kodama T.
    In Vivo; 2001 Jan 18; 15(4):319-25. PubMed ID: 11695224
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?
    Khoo SK, Chick P.
    Med J Aust; 1992 Jan 20; 156(2):124-32. PubMed ID: 1736053
    [Abstract] [Full Text] [Related]

  • 7. Hormone replacement therapy use and variations in the risk of breast cancer.
    Opatrny L, Dell'Aniello S, Assouline S, Suissa S.
    BJOG; 2008 Jan 20; 115(2):169-75; discussion 175. PubMed ID: 18081598
    [Abstract] [Full Text] [Related]

  • 8. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P, Fohlin H, Arnesson LG, Dufmats M, Nordenskjöld K, Nordenskjöld B, Stål O, South-East Sweden Breast Cancer Study Group.
    Acta Oncol; 2009 Jan 20; 48(4):504-13. PubMed ID: 19235568
    [Abstract] [Full Text] [Related]

  • 9. Hormone replacement therapy and estrogen-dependent cancers.
    Birkhäuser M.
    Int J Fertil Menopausal Stud; 1994 Jan 20; 39 Suppl 2():99-114. PubMed ID: 7874193
    [Abstract] [Full Text] [Related]

  • 10. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.
    J Natl Cancer Inst; 2005 Sep 07; 97(17):1254-61. PubMed ID: 16145046
    [Abstract] [Full Text] [Related]

  • 11. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.
    Canonico M, Fournier A, Carcaillon L, Olié V, Plu-Bureau G, Oger E, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Scarabin PY.
    Arterioscler Thromb Vasc Biol; 2010 Feb 07; 30(2):340-5. PubMed ID: 19834106
    [Abstract] [Full Text] [Related]

  • 12. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M, Rody A.
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun 01; 126(2):146-54. PubMed ID: 16621229
    [Abstract] [Full Text] [Related]

  • 13. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
    Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W, Korean Breast Cancer Society.
    J Clin Oncol; 2007 Jun 10; 25(17):2360-8. PubMed ID: 17515570
    [Abstract] [Full Text] [Related]

  • 14. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
    Olsson HL, Ingvar C, Bladström A.
    Cancer; 2003 Mar 15; 97(6):1387-92. PubMed ID: 12627501
    [Abstract] [Full Text] [Related]

  • 15. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 16. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE.
    Cancer; 2004 Sep 15; 101(6):1311-22. PubMed ID: 15368322
    [Abstract] [Full Text] [Related]

  • 17. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J.
    J Clin Oncol; 2006 Aug 20; 24(24):3991-6. PubMed ID: 16921052
    [Abstract] [Full Text] [Related]

  • 18. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
    Breast Cancer Res; 2008 Aug 20; 10(5):R88. PubMed ID: 18928543
    [Abstract] [Full Text] [Related]

  • 19. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT.
    Cancer; 2006 May 15; 106(10):2095-103. PubMed ID: 16598749
    [Abstract] [Full Text] [Related]

  • 20. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.